What Researchers Say About CART

Quotes from some of CART’s grant recipients:

Upon receiving CART’s fourth grant at the University of Pennsylvania, Dr. John Trojanowski commented: “Funding from sources like Rotarians allow us to jump-start scientific research on the many targets that we think are molecular pathways to curing Alzheimer’s. It is remarkable that just a few citizens can band together to recognize a need and with deliberation and foresight, deliver major awards on the level of a large foundation or government agency.”


Dr. Gary Landreth of Case Western Reserve University received a grant in 2001 to support work on a then-novel class of drugs. Dr. Landreth stated, “The CART funds were absolutely critical to our success, as they allowed us to pursue experiments investigating the mechanism of drug action for which we had no other means of support.” He further advised that this research has led to three phases of testing involving expenditures in excess of $200 million dollars. (another example of how CART “seed funds” may lead to major research grants from the National Institute of Health and other groups).


Drs. Allan Levey and Jim Lau of Emory University: Dr. Lau, commenting on the discovery of the SORL 1 gene and its connection to CART. “The connection is simple. Our work (funded by CART) led to the first association of the SORL 1 protein (also called LR 11) with AD. That sparked interest and led directly to the study of SOTL 1 and other related genes by a very large consortium of genetics researchers.”


Dr. Gary Small of UCLA: “our group remains deeply appreciative for the funding we received from your program several years ago. The CART Grants Program clearly helped us to move the field forward through its funding of our project, which led to improved understanding of our amyloid plaque and tau tangle PET technology in mild cognitive impairment.”


Dr. Sanjay Simplicar of Cleveland Clinic: “We have shown that a part of amyloid precursor protein, called AICD, causes tau to aggregate and we all know that tau aggregation is bad. Thus my findings that AICD could be the real culprit in AD have gained more credibility. Thus, the CART funding is supporting novel and cutting edge research.”


Dr. David Sweatt of the University of Alabama at Birmingham: “CART funding will be critical for my laboratory to be able to aggressively pursue a new drug development opportunity that we have, that hopefully will lead to a new type of treatment for Alzheimer’s disease.”



Dr. Todd Golde, Mayo Clinic, Jacksonville: “Through funding provided by the CART award we will evaluate how several different types of compounds that modulate production of the amyloid beta protein work to modulate amyloid beta protein deposition in the brain of an Alzheimer’s disease mouse model.” In a follow up two years after the CART grant was made, Dr. Golde commented: “… CART funding was vital in our getting an NIH grant renewed that has been awarded to both Eddie Koo and myself and is for $2.5 million dollars over 5 years.


Dr. Harry Levine, the University of Kentucky: “Thank you so much for allowing me to be part of the CART Fund annual meeting and to give those who worked so hard soliciting the funds that I will be using for research a taste of what we are trying to do. I was very much impressed with the dedication of the group and how much you have been able to accomplish, both in raising funds and awareness. I think that bringing in the grantees like this is a great way to build a personal bond between the organization and the researchers. It helps researchers remember the people who are working with us in this struggle to defeat an insidious disease. Sometimes research gets pretty lonely and it’s a reconnection like this that reminds me exactly why I work on Alzheimer’s disease… I will be in touch and hope that I will have exciting results to report soon.